Abstract:Introduction Oxytocin (OXT) is a neuropeptide associated with social behavior and the modulation of neural circuits related to social cognition and emotion regulation. Schizophrenia is a mental disorder that causes impairment in different areas of social cognition, including empathy. A systematic review of the literature showed positive effects of exogenous administration of this hormone on the empathy of individuals without psychopathology, especially in the affective domain. Studies on the effect of OXT on empathy in patients with schizophrenia are very limited, being restricted to the cognitive domain.ations must be overcome in future studies. The effects associated with chronic use of the hormone should be the subject of future studies. Objectives to evaluate the effect of a single dose of intranasal OXT (24UI) on affective empathy in individuals with refractory schizophrenia and healthy controls. Methods a double-blind, randomized, placebo-controlled clinical trial was conducted. A convenience sample of 51 adult men (mean age 34.4 ± 7.6, >10 years of education) was recruited, 20 of whom were diagnosed with refractory schizophrenia according to the DSM-5 (exclusively using clozapine or clozapine + mood stabilizer and/or benzodiazepine) and 31 healthy controls. They were randomized into four groups and received OXT or placebo (PLA – vehicle: SCH-OXT (N=11), SHC-PLA (N=9), HC-OXT (N=15), HC-PLA (N= 16)). Before and after 50 minutes of administering the substance, they performed an affective empathy task (Multifaceted Emphaty Test – MET). Results the baseline levels of affective empathy of patients with schizophrenia were lower compared to healthy controls when faced with negative stimuli (p=0.003), but not positive ones (p=0.39). After the administration of OXT and PLA (post-pre), a small increase in empathy levels was observed in all groups, which did not reach statistical significance (positive stimuli: ΔSCH-OXT = 0.16±1.08; ΔSHC-PLA= 0.53±1.44, ΔHC-OXT= 0.02±0.67, ΔHC-PLA= 0.24±0.45, p=0.85; negative stimuli: ΔSCH-OXT = 0.20±1.31; ΔSHC-PLA= 1.16±0.79, ΔHC-OXT= 0.12±0.99, ΔHC-PLA= 0.31±0.57, p=0.11). Conclusions the acute effects of intranasal OXT did not favor improvements in the levels of affective empathy, either in patients with schizophrenia or in healthy controls, contrary to the hypotheses of this study. The limited sample size and context-dependent aspects of OXT may explain these findings. These methodological limitations must be overcome in future studies. The effects associated with chronic use of the hormone should be the subject of future studies. Disclosure of Interest None Declared

In the eye of the beholder? Oxytocin effects on eye movements in schizophrenia

Endogenous oxytocin levels are associated with facial emotion recognition accuracy but not gaze behavior in individuals with schizophrenia

Oxytocin Facilitates Socially Directed Attention.

Oxytocin Facilitation of Emotional Empathy Is Associated With Increased Eye Gaze Toward the Faces of Individuals in Emotional Contexts

Acute effects of intranasal ocytocin on affective empathy of patients with refractory schizophrenia and healthy controls: results of a randomized clinical trial

Oxytocin Biases Eye-Gaze To Dynamic And Static Social Images And The Eyes Of Fearful Faces: Associations With Trait Autism

Eye-Tracking Reveals a Role of Oxytocin in Attention Allocation Towards Familiar Faces

Oxytocin enhances the recovery of eye-contact induced autonomic arousal: A treatment mechanism study with placebo-controlled design

Oxytocin Modulates Attention Switching Between Interoceptive Signals and External Social Cues

Oxytocin Enhances the Neural Efficiency of Social Perception

Attachment Anxiety Moderates the Effect of Oxytocin on Negative Emotion Recognition: Evidence from Eye-Movement Data

Oxytocin Reduces Top-Down Control of Attention by Increasing Bottom-Up Attention Allocation to Social but Not Non-Social Stimuli – A Randomized Controlled Trial

Oxytocin Enhances Attentional Bias for Neutral and Positive Expression Faces in Individuals with Higher Autistic Traits.

The effect of intranasal oxytocin on neurocognition in people with schizophrenia: A randomized controlled trial

Oral Administration of Oxytocin, Like Intranasal Administration, Decreases Top-Down Social Attention

Intranasal oxytocin modulates very early visual processing of emotional faces

Neurochemical effects of oxytocin in people at clinical high risk for psychosis

Effects of Chronic Intranasal Oxytocin on Visual Attention to Faces vs. Natural Scenes in Older Adults

Endogenous oxytocin response to film scenes of attachment and loss is pronounced in schizophrenia

Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin

The effect of oxytocin on biological motion perception in dogs (Canis familiaris)